Next Article in Journal
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study
Next Article in Special Issue
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Previous Article in Journal
Evaluation of Intensity- and Contour-Based Deformable Image Registration Accuracy in Pancreatic Cancer Patients
Previous Article in Special Issue
STAT3 and STAT5 Activation in Solid Cancers
Open AccessReview

STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases

1
Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057 Rostock, Germany
2
Department Life, Light & Matter, University of Rostock, 18059 Rostock, Germany
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(10), 1448; https://doi.org/10.3390/cancers11101448
Received: 8 August 2019 / Revised: 16 September 2019 / Accepted: 23 September 2019 / Published: 27 September 2019
(This article belongs to the Special Issue Targeting STAT3 and STAT5 in Cancer)
Melanoma is a skin cancer which can become metastatic, drug-refractory, and lethal if managed late or inappropriately. An increasing number of melanoma patients exhibits autoimmune diseases, either as pre-existing conditions or as sequelae of immune-based anti-melanoma therapies, which complicate patient management and raise the need for more personalized treatments. STAT3 and/or STAT5 cascades are commonly activated during melanoma progression and mediate the metastatic effects of key oncogenic factors. Deactivation of these cascades enhances antitumor-immune responses, is efficient against metastatic melanoma in the preclinical setting and emerges as a promising targeting strategy, especially for patients resistant to immunotherapies. In the light of the recent realization that cancer and autoimmune diseases share common mechanisms of immune dysregulation, we suggest that the systemic delivery of STAT3 or STAT5 inhibitors could simultaneously target both, melanoma and associated autoimmune diseases, thereby decreasing the overall disease burden and improving quality of life of this patient subpopulation. Herein, we review the recent advances of STAT3 and STAT5 targeting in melanoma, explore which autoimmune diseases are causatively linked to STAT3 and/or STAT5 signaling, and propose that these patients may particularly benefit from treatment with STAT3/STAT5 inhibitors. View Full-Text
Keywords: melanoma; autoimmune disease; inflammation; STAT3; STAT5; immunotherapy; tumor–immune cell interactions melanoma; autoimmune disease; inflammation; STAT3; STAT5; immunotherapy; tumor–immune cell interactions
Show Figures

Figure 1

MDPI and ACS Style

Logotheti, S.; Pützer, B.M. STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases. Cancers 2019, 11, 1448.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop